联讯仪器IPO背后：2024年净利刚扭亏，股权代持“惹眼”

Core Viewpoint - Suzhou Lianxun Instrument Co., Ltd. is seeking to go public on the Sci-Tech Innovation Board, with significant growth in revenue and profit expected in 2024, despite rising debt levels and past issues with shareholding arrangements [1][3]. Financial Performance - In 2024, the company achieved approximately 789 million yuan in revenue, a year-on-year increase of 185.87%, and a net profit of about 140 million yuan, marking a turnaround from previous losses [3]. - The company reported revenues of approximately 214 million yuan and 276 million yuan in 2022 and 2023, respectively, with net losses of 38.07 million yuan and 55.39 million yuan [3]. - In Q1 2025, the company continued its profitability with revenues of about 201 million yuan and a net profit of approximately 19.33 million yuan [3]. Fundraising Plans - The company plans to raise approximately 1.954 billion yuan through its IPO, with 150 million yuan allocated for working capital and the remainder for various R&D projects [4]. - As of Q1 2025, the company had cash reserves of about 254 million yuan, indicating a strong liquidity position despite the planned fundraising [4]. Debt Levels - The company's debt-to-asset ratio has been increasing, reaching approximately 51.03% by the end of the reporting period, significantly higher than the industry average [5]. - The debt-to-asset ratios for the reporting periods were approximately 26.71%, 41.08%, 47.66%, and 51.03%, compared to industry averages of 12.89%, 13.15%, 16.01%, and 15.29% [5]. Accounts Receivable - The company's accounts receivable balances increased over the reporting periods, with the balance at the end of the period reaching approximately 305 million yuan, accounting for 37.95% of revenue [6]. - The proportion of accounts receivable aged within one year remained high, indicating good quality and low collection risk [6]. R&D Investment - The company has invested significantly in R&D, with expenses of approximately 535.73 million yuan, 1.05 billion yuan, 1.91 billion yuan, and 568.06 million yuan over the reporting periods, representing 24.99%, 37.97%, 24.27%, and 28.25% of revenue, respectively [7]. - The company employs 385 R&D personnel as of March 2025, with plans to continue enhancing its R&D team [7]. Shareholding Structure - The chairman, Hu Haiyang, previously used a friend for shareholding representation during the company's establishment, which has raised concerns about ownership transparency [8][10]. - As of the signing of the prospectus, Hu directly holds 20.55% of the company and controls a total of 54.79% of shares through various platforms [8][9]. Legal Issues - The company is currently involved in ongoing litigation related to a patent infringement dispute with Aehr, which remains unresolved as of the prospectus signing date [10].